Sylvan is a fungal biotechnology company specializing in mushroom spawn production and developing new bio-products.

Supira Medical, Inc. is developing the Supira System, a percutaneous ventricular assist device (pVAD) designed to provide hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients.

Hillstar Bio is a biotechnology company developing immunology therapies that selectively target and deplete pathogenic immune cells to treat autoimmune diseases.

Augustine Therapeutics is a biotechnology company developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through selective inhibition of the HDAC6 enzyme.

Callio Therapeutics develops multi-payload antibody-drug conjugates for cancer therapy.

Biocomposites develops innovative calcium compounds and bone cements for surgical use.

Newleos Therapeutics is a clinical-stage neuroscience company developing therapies for neuropsychiatric disorders, including anxiety and cognitive impairments, with a focus on first-in-class and best-in-class treatments.

Commit Biologics develops a Bispecific Complement Engaging (BiCE™) platform to target cancer and autoimmune diseases.

Windward Bio is a clinical-stage drug development company focused on creating treatments for severe respiratory conditions, including asthma and COPD, using long-acting monoclonal antibodies and bispecifics.

AnaCardio is a biopharmaceutical company developing an oral ghrelin receptor agonist to treat heart failure with reduced ejection fraction.

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Coave Therapeutics develops genetic medicines using their ALIGATER™ platform to enhance treatment for CNS, neuromuscular, and eye diseases.

FIRE1 is a connected medical device solutions company focused on developing a heart failure management platform that enables patient self-management and reduces healthcare burdens.

Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.

SiteOne Therapeutics is a biopharmaceutical company developing selective, small molecule ion channel modulators for treating sensory hyperexcitability disorders like pain and chronic cough.

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Antag Therapeutics is a biopharmaceutical company developing treatments for obesity and cardiometabolic diseases, focusing on injectable therapies like their novel GIPR antagonist, AT-7687.

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Quanta Dialysis Technologies develops and markets the Quanta™ Dialysis System, a device for home hemodialysis, aiming to expand its presence in the acute care segment.

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates for cancer treatment.

AvenCell Therapeutics, Inc. develops a Universal Switchable CAR-T cell therapy platform for treating hematologic malignancies and autoimmune diseases.

Qure.ai develops AI-driven solutions for early disease detection and has deployed its technology globally.

Convergent Therapeutics is a clinical-stage biotechnology company developing radiopharmaceutical treatments for cancer, including a lead candidate for metastatic castration-resistant prostate cancer.

Hoba Therapeutics is a biotech firm specializing in developing novel treatments for painful Chemotherapy-Induced Peripheral Neuropathy and sensorineural hearing loss, currently advancing their lead drug candidate, HB-086, towards Phase 1 clinical trials.

energyRe is a U.S.-based clean energy developer focused on expanding its renewable energy portfolio through utility-scale transmission and storage, onshore and offshore wind, and solar generation to decarbonize American cities and advance the U.S. clean energy transition.

NMD Pharma is a biotech company focused on developing small molecule therapies for neuromuscular diseases by targeting the skeletal muscle chloride ion channel (ClC-1).

Terremoto Biosciences is a biotechnology company that has raised $175 million in a Series B financing round to advance its platform and support the development of multiple in-house programs targeting diseases of high unmet medical need.

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for brain disorders, with plans to advance their pipeline programs, including ML-007C-MA, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, as well as support their other pipeline programs.

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

LimmaTech Biologics is a Swiss company that develops vaccines against multidrug-resistant bacterial infections, with a focus on shigellosis and gonorrhea, using E. coli expression systems.

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Acesion Pharma is a biotech company that develops therapies for atrial fibrillation, specifically focusing on the clinical development of an SK ion channel inhibitor for chronic oral treatment.